



SINGAPORE O&G LTD.
CARING FOR WOMEN'S & CHILDREN'S HEALTH

SINGAPORE O&G LTD.

(Company Registration No. 201100687M)
(Incorporated in the Republic of Singapore)

MINUTES of the Annual General Meeting (the “**AGM**” or “**Meeting**”) of Singapore O&G Ltd. (the “**Company**” or “**SOG**”) held via live webcast and audio conference on Friday, 23 April 2021 at 10.00 a.m.

Present:

Directors:

Dr. Beh Suan Tiong (Chairman of the Board and AGM)
Dr. Heng Tung Lan (Executive Director)
Mr. Ng Boon Yew (Lead Independent Director)
Mr. Chan Heng Toong (Independent Director)
Mr. Chooi Yee-Choong (Independent Director)
Ms. See Tho Soat Ching (Independent Director)

Shareholders:

As set out in the attendance list maintained by the Company

In Attendance:

SOG

Eric Choo (Chief Executive Officer)
Doreen Chew (Chief Financial Officer)

Tricor Evatthouse Corporate Services

Chong Pei Wen
Sheryl Sim

Tricor Barbinder Share Registration Services (Scrutineers)

Tan Jack Leng
Audrey Leong

Trusted Services (Polling Agents)

Keown Goh

Invitees:

SOG

Angeline Ng
Vikki Chan
Ng Boon Khai

Singapore O&G Ltd.
Minutes of the Annual General Meeting held on 23 April 2021

PrimePartners Corporate Finance Pte. Ltd.
Jennifer Tan
Lim Joe Min

Foo Kon Tan LLP
Chan Ser

CHAIRMAN

Dr. Beh Suan Tiong (“**Dr. Beh**”), the Chairman of the Meeting and Board of Directors welcomed all shareholders for their attendance. The Chairman introduced the Executive Director, Dr. Heng Tung Lan (“**Dr. Heng**”) and the Chief Executive Officer, Mr. Eric Choo (“**Mr. Choo**”) present at the AGM venue and the other members of the Board, Chief Financial Officer, Ms. Doreen Chew and Auditors, Mr. Chan Ser, to the shareholders. The Chairman further informed that Dr. Lee Keen Whye has extended his apologies to the shareholders for not being able to attend the AGM.

The Chairman thanked the shareholders who pre-registered with the Company, watched and listened to the proceedings through live webcast and audio conference. He also acknowledged their attendance in this Meeting.

QUORUM

With the requisite quorum being present, the Chairman called the meeting to order at 10.00 a.m.

NOTICE

The notice of the meeting having been circulated to the members, with the concurrence of the Meeting, was taken as read.

POLL VOTING

The Chairman recapped that shareholders had been informed via the Company's announcement made on SGXNet on 8 April 2021 that they would not be able to vote through live webcast or audio conference. The only way for shareholders to exercise their voting rights was to appoint the Chairman of the Meeting as proxy. The Chairman informed that in his capacity as Chairman of the Meeting, he has been appointed as a proxy by some shareholders and that he had voted in accordance with their instructions, which had been accounted for in the polling for the resolutions.

The Chairman further informed shareholders that, all proposed resolutions tabled at this Meeting would be voted by way of poll via proxy voting pursuant to Singapore Exchange Securities Trading Limited, Listing Manual Section B: Rules of Catalist (“**Rules of Catalist**”) 730A(2) and no voting would be conducted in the Meeting.

POLLING AGENT AND SCRUTINEER

The Chairman informed the Meeting that the Company has appointed Messrs. Trusted Services as polling agent and Messrs. Tricor Barbinder Share Registration Services as scrutineers for the Meeting. The validity of the proxy forms submitted by the shareholders by the deadline of 21 April 2021, 10.00 a.m. had been reviewed and the votes of all such valid proxy forms had been counted by the polling agent and verified by the scrutineers.

PRESENTATION

Prior to the business of the AGM, Mr. Choo delivered a corporate presentation on the business overview, financial highlights for the financial year ended 31 December 2020 and corporate updates and future plans.

The corporate presentation slides are attached herewith as [Appendix A](#).

QUESTIONS AND RESPONSES

The Chairman informed the Meeting that the Company has received questions from the shareholders prior to the AGM. All questions have been addressed by the Company and the responses were published on the SGXNet on 21 April 2021. The responses to the questions can also be found at the Company's corporate website.

For the benefit of the shareholders, the Board and Management recapped the substantial and relevant questions received from the shareholders in the Meeting. The questions and responses are set out in [Appendix B](#) annexed to these minutes.

After recapping all questions received from the shareholders, the Chairman proceeded with the business of the AGM.

Ordinary Resolution 1

ADOPTION OF AUDITED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2020 AND DIRECTORS' STATEMENT AND THE INDEPENDENT AUDITOR'S REPORT

The Chairman proposed the following motion:

"RESOLVED that the Audited Financial Statements of the Company for the financial year ended 31 December 2020 together with the Directors' Statement and Independent Auditor's Report be and are hereby received and adopted."

The Chairman announced the poll results for the resolution as annexed in [Appendix C](#).

Based on the results, the Chairman declared Resolution 1 carried.

Ordinary Resolution 2

DECLARATION OF FINAL DIVIDEND

The Chairman informed shareholders that the proposed dividend of 1.20 Singapore cents per ordinary share, if approved at the AGM, will be paid on 21 May 2021.

The Chairman proposed the following motion:

“RESOLVED that a tax exempt (one-tier) final dividend of 1.20 Singapore cents per ordinary share in respect of the financial year ended 31 December 2020 be and is hereby approved.”

The Chairman announced the poll results for the resolution as annexed in [Appendix C](#).

Based on the results, the Chairman declared Resolution 2 carried.

Ordinary Resolution 3

RETIREMENT AND RE-ELECTION OF DR. LEE KEEN WHYE PURSUANT TO ARTICLE 91 OF THE COMPANY'S CONSTITUTION

Dr. Lee retired pursuant to Article 91 of the Company's Constitution. Dr. Lee being eligible had offered himself for re-election.

The Chairman informed shareholders that upon re-election, Dr. Lee would remain as the Executive Director of the Company.

The Chairman proposed the following motion:

“RESOLVED that Dr. Lee Keen Whye be re-elected as a Director of the Company.”

The Chairman announced the poll results for the resolution as annexed in [Appendix C](#).

Based on the results, the Chairman declared Resolution 3 carried.

Ordinary Resolution 4

RETIREMENT AND RE-ELECTION OF MR. NG BOON YEW PURSUANT TO ARTICLE 91 OF THE COMPANY'S CONSTITUTION

Mr. Ng Boon Yew (“**Mr. Ng**”) retired pursuant to Article 91 of the Company's Constitution. Mr. Ng being eligible had offered himself for re-election.

The Chairman informed shareholders that upon re-election, Mr. Ng would remain as the Lead Independent Director, the Chairman of the Audit Committee and a member of the Nominating Committee. Mr. Ng shall be considered independent for the purposes of Rule 704(7) of the Rules of Catalyst.

The Chairman proposed the following motion:
“RESOLVED that Mr. Ng Boon Yew be re-elected as a Director of the Company.”

The Chairman announced the poll results for the resolution as annexed in [Appendix C](#).

Based on the results, the Chairman declared Resolution 4 carried.

RETIREMENT OF MR. CHAN HENG TOONG PURSUANT TO ARTICLE 91 OF THE COMPANY’S CONSTITUTION

The Meeting noted that Mr. Chan Heng Toong (“**Mr. Chan**”), the Independent Director of the Company was subject to retirement by rotation in accordance with Article 91 of the Company’s Constitution at the AGM. He has given a notice to the Company that he would not seek for re-election at the AGM to enable younger independent directors to come in to rejuvenate the Board and to focus on his personal commitments. Accordingly, Mr Chan ceased to be an Independent Director of the Company, the Chairman of Nominating Committee and a member of the Audit and Remuneration Committees upon the conclusion of the AGM.

The Board took the opportunity to record its heartfelt gratitude to Mr. Chan for his past service and contribution during his tenure as an Independent Director of the Company.

Ordinary Resolution 5

PAYMENT OF INDEPENDENT DIRECTORS’ FEES OF S\$168,000 FOR FINANCIAL YEAR ENDED 31 DECEMBER 2020

The Chairman proposed the following motion:

“RESOLVED that the payment of Independent Directors’ fees of S\$168,000 for the financial year ended 31 December 2020 be approved.”

The Chairman announced the poll results for the resolution as annexed in [Appendix C](#).

Based on the results, the Chairman declared Resolution 5 carried.

Ordinary Resolution 6

RE-APPOINTMENT OF AUDITORS

The Chairman informed shareholders that Foo Kon Tan LLP have expressed their willingness to accept re-appointment.

The Chairman proposed the following motion:

“RESOLVED that Messrs. Foo Kon Tan LLP be and are hereby re-appointed as Auditors of the Company to hold office until the conclusion of the next Annual General Meeting of the Company at a remuneration to be fixed by the directors.”

The Chairman announced the poll results for the resolution as annexed in [Appendix C](#).

Based on the results, the Chairman declared Resolution 6 carried.

SPECIAL BUSINESS:

Ordinary Resolution 7

AUTHORITY TO ALLOT AND ISSUE SHARES (the “Share Issue Mandate”)

The Chairman proposed the following motion:

“RESOLVED that pursuant to Section 161 of the Companies Act, Chapter. 50 of Singapore (“Companies Act”) and Rule 806 of the Rules of Catalist, the Directors of the Company be authorised and empowered to:

- (a) (i) *allot and issue shares in the Company (“Shares”) whether by way of rights, bonus or otherwise; and/or*
- (ii) *make or grant offers, agreements or options (collectively, “Instruments”) that might or would require Shares to be issued, including but not limited to the creation and issue of (as well as adjustments to) options, warrants, debentures or other instruments convertible into Shares,*

at any time and upon such terms and conditions and for such purposes and to such persons as the Directors of the Company may in their absolute discretion deem fit; and
- (b) *(notwithstanding the authority conferred by this Resolution may have ceased to be in force) issue Shares in pursuance of any Instruments made or granted by the Directors of the Company while this Resolution was in force,*

provided that:

- (1) *the aggregate number of Shares to be issued pursuant to this Resolution (including Shares to be issued in pursuance of the Instruments, made or granted pursuant to this Resolution) shall not exceed one hundred percent (100%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below), of which the aggregate number of Shares to be issued other than on a pro-rata basis to existing shareholders of the Company (including Shares to be issued in pursuance of the Instruments, made or granted pursuant to this Resolution) shall not*

exceed fifty percent (50%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below);

- (2) *(subject to such calculation as may be prescribed by the SGX-ST) for the purpose of determining the aggregate number of Shares that may be issued under sub-paragraph (1) above, the total number of issued Shares (excluding treasury shares and subsidiary holdings) shall be based on the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company at the time of the passing of this Resolution, after adjusting for:*
- (a) *new Shares arising from the conversion or exercise of any convertible securities;*
 - (b) *new Shares arising from exercising share options or vesting of share awards provided that the share options or share awards (as the case may be) were granted in compliance with Part VIII of Chapter 8 of the Catalist Rules; and*
 - (c) *any subsequent bonus issue, consolidation or subdivision of Shares;*

Adjustments in accordance with (a) and (b) above are only to be made in respect of new Shares arising from convertible securities, share options or share awards which were issued and outstanding or subsisting at the time of the passing of this Resolution;

- (3) *in exercising the authority conferred by this Resolution, the Company shall comply with the requirements imposed by the SGX-ST from time to time and the provisions of the Catalist Rules for the time being in force (unless such compliance has been waived by the SGX-ST) all applicable requirements under the Companies Act and otherwise, and the Constitution for the time being of the Company; and*
- (4) *unless revoked or varied by the Company in a general meeting, such authority shall continue in force until the conclusion of the next Annual General Meeting of the Company or the date on which the next Annual General Meeting of the Company is required by law and the Catalist Rules to be held, whichever is earlier.”*

The Chairman announced the poll results for the resolution as annexed in [Appendix C](#).

Based on the results, the Chairman declared Resolution 7 carried.

Ordinary Resolution 8

PROPOSED RENEWAL OF THE SHARE BUYBACK MANDATE

The Chairman informed the Meeting that Dr. Heng have abstained from voting of this resolution.

The Chairman proposed the following motion:

“RESOLVED that:

(1) *for the purposes of the Catalist Rules and the Companies Act, the Directors be and are hereby authorised to exercise all the powers of the Company to purchase or otherwise acquire the issued ordinary shares in the capital of the Company not exceeding in aggregate the Maximum Limit (as defined below), at such price(s) as may be determined by the Directors from time to time up to the Maximum Price (as defined below), whether by way of:*

(a) *on-market purchase(s) (each a “**Market Purchase**”) which are transacted on the SGX-ST or, as the case may be, any other securities exchange on which the Shares may for the time being be listed and quoted, and which may be transacted through one or more duly licensed stockbrokers appointed by the Company for the purpose; and/or*

(b) *off-market purchase(s) (each an “**Off-Market Purchase**”), which are purchases of Shares effected otherwise than on an approved exchange in Singapore or any securities exchange outside Singapore, in accordance with any equal access scheme(s) as may be determined or formulated by the Directors as they consider fit, which scheme(s) shall satisfy all the conditions prescribed by the Constitution and the Catalist Rules;*

*and otherwise in accordance with all other laws and regulations, including but not limited to, the provisions of the Companies Act and the Catalist Rules as may for the time being be applicable, be and is hereby authorised and approved generally and unconditionally (the “**Share Buyback Mandate**”);*

(2) *unless varied or revoked by the members of the Company in a general meeting, the authority conferred on the Directors pursuant to the Share Buyback Mandate may be exercised by the Directors at any time and from time to time during the period commencing from the date of the passing of this Resolution and expiring on the earlier of:*

(a) *the date on which the next AGM is held or required by law or the Constitution to be held;*

(b) *the date on which the purchases or acquisitions of Shares by the Company pursuant to the Share Buyback Mandate are carried out to the full extent mandated; or*

(c) *the date on which the authority contained in the Share Buyback Mandate is varied or revoked by an ordinary resolution of the Shareholders in a general meeting.*

(3) *in this Resolution:*

*“**Maximum Limit**” means that number of issued Shares representing ten percent (10%) of the total number of issued Shares as at the date of the passing of this Resolution, unless the Company has effected a reduction of the share capital of the*

Company in accordance with the applicable provisions of the Companies Act, at any time during the Relevant Period, in which event the total number of Shares shall be taken to be the total number of issued Shares as altered (excluding any treasury shares and subsidiary holdings that may be held by the Company from time to time). Any shares which are held as treasury shares and subsidiary holdings will be disregarded for purposes of computing the ten percent. (10%) limit;

“Relevant Period” means the period as set out in sub-paragraph (2) above; and

“Maximum Price”, in relation to a Share to be purchased or acquired, means the purchase price (excluding brokerage, stamp duties, commission, applicable goods and services tax and other related expenses) which shall not exceed:

- (a) in the case of a Market Purchase, one hundred and five percent (105%) of the Average Closing Price; and*
- (b) in the case of an Off-Market Purchase pursuant to an equal access scheme, one hundred and twenty percent. (120%) of the Average Closing Price,*

where:

“Average Closing Price” means the average of the closing market prices of the Shares over the last five (5) market days, on which transactions in the Shares were recorded, before the day of the Market Purchase of the Company, or as the case may be, before the day of the making of the offer pursuant to the Off-Market Purchase, and deemed to be adjusted for any corporate action that occurs during the relevant five (5) market days period and the day on which the purchases are made;

“day of the making of the offer” means the day on which the Company announces its intention to make an offer for an Off-Market Purchase, stating therein the purchase price (which shall not be more than the Maximum Price for an Off-Market Purchase calculated on the foregoing basis) for each Share and the relevant terms of the equal access scheme for effecting the Off-Market Purchase; and

- (4) the Directors of the Company and/or any of the Directors be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) as they and/or he/she may consider necessary, expedient, incidental or in the interests of the Company to give effect to the Share Buyback Mandate and/or this Resolution.”*

The Chairman announced the poll results for the resolution as annexed in [Appendix C](#).

Based on the results, the Chairman declared Resolution 8 carried.

Ordinary Resolution 9

AUTHORITY TO GRANT OPTIONS AND ISSUE SHARES UNDER SOG EMPLOYEE SHARE OPTION SCHEME

Chairman explained that the SOG Employee Share Option Scheme and Performance Share Plan enable the Company to reward the Directors and employees for their past contributions and services and provide incentives to the employees to achieve higher standards of performance. In addition, the Company's option scheme and plan would also align the interest of its employees and shareholders to continue to make significant contributions to the long term growth of the Group.

The Chairman proposed the following motion:

“RESOLVED that, pursuant to Section 161 of the Companies Act, the Directors of the Company be and are hereby authorised to offer and grant options in accordance with the provisions of the SOG Employee Share Option Scheme (the “Scheme”) and to allot and issue from time to time such Shares as may be required to be issued pursuant to the exercise of the options granted or to be granted under the Scheme provided always that the aggregate number of Shares issued and issuable in respect of all options granted or to be granted under the Scheme, all awards granted or to be granted under the SOG Performance Share Plan and all Shares, options or awards granted or to be granted under any other share option schemes or share plans of the Company, shall not exceed fifteen percent (15%) of the total number of issued Shares excluding treasury shares and subsidiary holdings of the Company.”

It was noted that all the Directors and employees of SOG as per [Appendix D](#) have abstained from voting of this Resolution, other than as a proxy/proxies where specific instructions had been given in the proxy form on how the vote is to be cast for this Resolution.

The Chairman announced the poll results for the resolution as annexed in [Appendix C](#).

Based on the results, the Chairman declared Resolution 9 carried.

Ordinary Resolution 10

AUTHORITY TO GRANT AWARDS AND ISSUE SHARES UNDER THE SOG PERFORMANCE SHARE PLAN

The Chairman proposed the following motion:

“RESOLVED that, pursuant to Section 161 of the Companies Act, the Directors of the Company be and are hereby authorised to grant awards in accordance with the provisions of the SOG Performance Share Plan (the “Plan”) and to allot and issue from time to time such Shares as may be required to be issued pursuant to the Plan provided always that the aggregate number of Shares to be issued pursuant to the Plan, when added to the number of shares issued and issuable or existing Shares delivered and deliverable in respect of all awards granted or to be granted under the Plan, all options granted or to be granted under the Scheme and all shares, options or awards granted under any other share scheme of

the Company, shall not exceed fifteen percent (15%) of the total number of issued Shares excluding treasury shares and subsidiary holdings of the Company.”

It was noted that all the Directors and employees of SOG as per [Appendix D](#) have abstained from voting of this Resolution, other than as a proxy/proxies where specific instructions had been given in the proxy form on how the vote is to be cast for this Resolution.

The Chairman announced the poll results for the resolution as annexed in [Appendix C](#).

Based on the results, the Chairman declared Resolution 10 carried.

CONCLUSION

There being no other business, the Meeting concluded at 10.39 a.m. with a vote of thanks to the Chairman and shareholders who attended the Meeting.

Confirmed as correct record of meeting,

Chairman of the Meeting
Dr. Beh Suan Tiong

Appendix C

SINGAPORE O&G LTD.
 (the “Company” or “SOG”)
 (Company Registration No. 201100687M)
 (Incorporated in the Republic of Singapore)

ANNUAL GENERAL MEETING
23 APRIL 2021

The results of the poll on each of the resolution put to vote at the AGM are set out below:-

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST	
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
1. Adoption of Directors’ Statement and Audited Financial Statements for the financial year ended 31 December 2020 and the Independent Auditor’s Report thereon	203,747,502	203,747,502	100	0	0
2. Declaration of a tax exempt (one-tier) final dividend of 1.20 Singapore cents per ordinary share for the financial year ended 31 December 2020	203,747,502	203,747,502	100	0	0
3. Re-election of Director pursuant to Article 91 – Dr. Lee Keen Whye	203,747,502	201,145,616	98.72	2,601,886	1.28
4. Re-election of Director pursuant to Article 91 – Mr. Ng Boon Yew	203,747,502	203,562,102	99.91	185,400	0.09
5. Approval of the Independent Directors’ fees of S\$168,000 for the financial year ended 31 December 2020	203,747,502	203,747,502	100	0	0

Singapore O&G Ltd.
Minutes of the Annual General Meeting held on 23 April 2021

Resolution number and details		Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
6.	Re-appointment of Messrs Foo Kon Tan LLP as Auditors of the Company and to authorise the Directors to fix their remuneration.	203,747,502	203,747,502	100	0	0
7.	Authority to allot and issue shares pursuant to the Share Issue Mandate	203,747,502	202,962,102	99.61	785,400	0.39
8.	Proposed Renewal of Share Buyback Mandate	63,293,888	63,293,888	100	0	0
9.	Authority to grant options and issue shares under SOG Employee Share Option Scheme	4,020,886	3,835,486	95.39	185,400	4.61
10.	Authority to grant awards and to issue shares under SOG Performance Share Plan	4,020,886	3,835,486	95.39	185,400	4.61

Appendix D

SINGAPORE O&G LTD.
(the “Company” or “SOG”)
(Company Registration No. 201100687M)
(Incorporated in the Republic of Singapore)

**ANNUAL GENERAL MEETING
23 APRIL 2021**

Details of parties who have abstained from voting on any resolution are set out below:

<u>Ordinary Resolution 8</u>	
Proposed Renewal of the Share Buyback Mandate	
Name	Total number of shares
Heng Tung Lan	140,453,614

<u>Ordinary Resolution 9</u>	
Authority to grant options and to issue shares under the SOG Employee Share Option Scheme	
Name	Total number of shares
Choo Kok Wei, Eric	350,000
Citibank Nominees Singapore Pte Ltd	58,923,002
Heng Tung Lan	140,453,614

<u>Ordinary Resolution 10</u>	
Authority to grant awards and to issue shares under the SOG Performance Share Plan	
Name	Total number of shares
Choo Kok Wei, Eric	350,000
Citibank Nominees Singapore Pte Ltd	58,923,002
Heng Tung Lan	140,453,614

This announcement has been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”) and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms. Jennifer Tan, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.



SINGAPORE O&G LTD.
CARING FOR WOMEN'S & CHILDREN'S HEALTH

Annual General Meeting Corporate Presentation

23 April 2021

DISCLAIMER

This Corporate Presentation has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms. Jennifer Tan, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.

OVERVIEW

OUR SERVICES



General obstetrics, labour & delivery

Gynaecological Surgery

Medical problems during pregnancy

General gynaecology

Obstetrical complication & its management

Female pelvic medicine / Urogynaecology & reconstruction surgery



Gynae-oncological surgery

Breast & general surgery

Colorectal surgery, diagnostic & therapeutic endoscopic procedures



New born & well-baby checks

Common childhood conditions

Childhood immunisation routine & vaccinations

Child nutrition, growth and developmental assessment

Gastrointestinal conditions & endoscopic procedures

Respiratory & behavioural sleep conditions



General skin care

Aesthetics & dermatological procedures

Dermatological surgery & laser surgery

OUR NETWORK

Strategically located clinics throughout Singapore for easy accessibility



FINANCIAL HIGHLIGHTS

FINANCIAL HIGHLIGHTS




S\$'000	FY 2020	FY 2019	Change (%)
Revenue	39,889	39,757	0.3%
Other operating income	1,435	449	N/M
Consumables and medical supplies used	(6,705)	(6,466)	3.7%
Employee remuneration expense	(19,472)	(16,481)	18.1%
Depreciation	(2,177)	(2,207)	(1.4%)
Other operating expense	(2,192)	(2,503)	(12.4%)
Profit from operations	10,778	12,549	(14.1%)
Impairment of goodwill	-	(11,900)	(100.0%)
Finance income	184	153	20.3%
Finance expense	(154)	(183)	(15.8%)
Net finance income/(expense)	30	(30)	N/M
Income tax expense	(1,315)	(1,752)	(24.9%)
Net profit for the year	9,493	(1,133)	N/M


N/M: Not meaningful

REVENUE

Revenue (S\$'000)



Revenue by Business Segments




PROFIT FROM OPERATIONS

Profit from Operations (S\$'000)




Profit from Operations by Business Segments (S\$'000)




NET PROFIT AFTER TAX

Net Profit/(Loss) (S\$'000)




Earnings Per Share
(Singapore cents)



NET TANGIBLE ASSETS

Net Tangible Asset Value (S\$'000)



Net Tangible Asset Value Per Share (Singapore cents)



* For better comparison, the net tangible asset value per ordinary shares as at 31 December 2016 has been adjusted for the increase in the number of ordinary shares resulting from the Share Split in May 2017.

FINANCIAL REVIEW



S\$'000	As at 31 December 2020	As at 31 December 2019
Key Assets		
Goodwill	12,230	12,230
Plant and equipment	1,489	1,595
Right-of-use assets	3,164	3,698
Inventories	1,908	2,030
Trade and other receivables	3,552	3,517
Cash and cash equivalents	35,514	25,985
Key Liabilities *		
Trade and other payables	8,936	6,412
Lease liabilities	3,301	3,815

* The Group does not have any borrowings and debt securities as at 31 December 2020 and 31 December 2019.

DIVIDEND



Dividend Per Share

FY 2020:

1.70 Singapore cents based on 476,085,402 shares for interim dividend and 475,469,678 shares for final dividend.

FY 2019:

0.62 Singapore cents based on 476,803,002 shares for interim dividend.

FY 2018:

1.70 Singapore cents based on 476,803,002 shares for interim and final dividend.

FY 2017:

1.50 Singapore cents based on 476,803,002 shares for interim and final dividend.


FY 2016:

3.10 Singapore cents based on 238,401,501 shares for interim and final dividend.

CORPORATE UPDATES & FUTURE PLANS

NUMBER OF BIRTHS


Historical Live Births in Singapore*




* <https://www.ica.gov.sg/stats> "Singapore Demographic Bulletin ('SDB')"




No. of Babies Delivered by SOG




NUMBER OF SURGERIES PERFORMED

 No. of GynaeOncological Surgeries



 No. of Breast Surgeries



FUTURE PLANS

STRENGTHEN

Strengthen SOG's brand awareness and increase market share



RECRUIT

Recruit more Specialist Medical Practitioners to strengthen all business segments



REFERRALS

Increase the level of inter-clinic referrals through synergy awareness



GROW

Continue to grow non-O&G business segments to increase their revenue and profit contribution to the Group



PARTNERSHIPS

Identify opportunities in business partnerships and collaborations, venture into humanitarian and other ancillary perspective



OUR SPECIALIST MEDICAL PRACTITIONERS



OBSTETRICS & GYNAECOLOGY



Dr. Beh Suan Tiong
EXECUTIVE CHAIRMAN

Date of Appointment
July 2013

Clinic
Thomson Medical Centre
#05-03

Specialisations
Advanced reproductive surgeries
and minimally invasive surgery (key
hole surgery), namely laparoscopic
and hysteroscopic surgery



Dr. Choo Wan Ling

Date of Appointment
July 2013

Clinic
Mount Elizabeth Novena
Specialist Centre #10-30

Specialisations
Antenatal care and risk assessment,
vaginal assisted and caesarean
delivery, and treatment of
gynaecological issues such as
endometriosis, uterine fibroids fertility
challenges and ovarian cysts



Dr. Heng Tung Lan
FOUNDER & EXECUTIVE DIRECTOR

Date of Appointment
January 2011

Clinic
Parkway East Medical Centre
#02-08

Specialisations
Pregnancy care and delivery,
female health screening,
menopause and female
wellness enhancement

OBSTETRICS & GYNAECOLOGY



Dr. Hong Sze Ching

Date of Appointment
July 2016

Clinic
Mount Alvernia Medical Centre
Block D #07-62

Specialisations
Obstetric care, management of
general gynaecological conditions,
laparoscopic surgery and
colposcopy



Dr. Lee Keen Whye

FOUNDER & EXECUTIVE DIRECTOR

Date of Appointment
January 2011

Clinic
Gleneagles Medical Centre
#08-15/16

Specialisations
Endoscopic work, especially
hysteroscopy, laparoscopy and
vaginal rejuvenation

OBSTETRICS & GYNAECOLOGY



Dr. Natalie Chua

Date of Appointment
August 2013

Clinic
Parkway East Medical Centre
#02-07

Specialisations
Obstetric care – preconception health screening, antenatal care and delivery

Management of common gynaecological problems



Dr. Clara Ong

Date of Appointment
May 2019

Clinic
Gleneagles Medical Centre
#08-15/6

Specialisations
Pregnancy care, menopausal care, family planning, management of general gynaecological conditions and colposcopy

CANCER-RELATED



DR. CINDY PANG

Consultant obstetrician & gynaecologist
Cynaecologist
MBBS (SINGAPORE), MMED (O&G),
MRCOG (UK)

Dr. Cindy Pang

Date of Appointment
December 2014

Clinic
Mount Elizabeth Novena
Specialist Centre #08-25

Specialisations
Antenatal care to expectant mothers and manages a wide range of conditions related to the female reproductive system

Main sub-specialty in gynaecological cancers and complex pelvic surgeries



DR. SIM HSIEN LIN

Consultant general surgeon
(colorectal surgery)
MBBS (SINGAPORE), MRCS (EDINBURGH),
MMED (GENERAL SURGERY),
FRCS (EDINBURGH)

Dr. Sim Hsien Lin

Date of Appointment
April 2021

Clinic
Mount Elizabeth Novena
Specialist Centre #06-53

Specialisations
General surgery with sub-specialty in colorectal surgery, surgical management of inflammatory bowel diseases, complex anal fistula, as well as transanal endoscopic microsurgery, diagnostic and therapeutic endoscopic procedures

DERMATOLOGY



DR. JOYCE LIM

Consultant dermatologist
MBBS (MALAYSIA), FRCPI (IRELAND),
FAMS (SINGAPORE)

Dr. Joyce Lim

Date of Appointment
January 2016

Clinic
Paragon Medical Suites
#11-16/20

Specialisations
Children and adult medical
dermatology including skin, hair
and nail problems, aesthetic skin
problems, laser and skin surgery



DR. LIEW HUI MIN

Consultant dermatologist
MBCHB (UK), MRCP (UK),
FAMS (SINGAPORE)

Dr. Liew Hui Min

Date of Appointment
December 2018

Clinic
Gleneagles Medical Centre
#06-01

Specialisations
General medical adult
dermatology, women's and
children's dermatology and
genital dermatology

PAEDIATRICS



Dr. Lim Xue Yan

Date of Appointment
July 2017

Clinic
Parkway East Medical Centre
#04-06

Specialisations
General paediatrics which includes new-born and well-baby screening, children immunisation, developmental assessment and behavioural care advice, nutrition and growth advice, and management of common childhood conditions like asthma



Dr. Irene Teo

Date of Appointment
November 2017

Clinic
11A Boon Tiong Road
#01-11

Specialisations
General paediatrics which includes new-born and well-baby screening, children immunisation, developmental assessment and behavioural care advice, nutrition and growth advice, and management of common childhood conditions including skin conditions

PAEDIATRICS



Dr. Christina Ong

Date of Appointment
November 2018

Clinic
Mount Elizabeth Novena
Specialist Centre #07-53

Specialisations
Management of children with gastrointestinal conditions and performing endoscopic procedures, as well as treating children with general medical conditions



Dr. Petrina Wong

Date of Appointment
February 2019

Clinic
Gleneagles Medical Centre
#08-14

Specialisations
General paediatrics with special interest in childhood respiratory and sleep conditions like pneumonia, asthma, sleep apnea, cough, allergies, parasomnias and behavioural sleep problems



SINGAPORE O&G LTD.
CARING FOR WOMEN'S & CHILDREN'S HEALTH

THANK YOU

OBSTETRICS &
GYNAECOLOGY



PAEDIATRICS



CANCER-
RELATED



DERMATOLOGY





SINGAPORE O&G LTD.
CARING FOR WOMEN'S & CHILDREN'S HEALTH

SINGAPORE O&G LTD.
(Company Registration No. 201100687M)

ANNUAL GENERAL MEETING 2021 – QUESTIONS AND RESPONSES

The Board of Directors (the “**Board**”) of Singapore O&G Ltd. (“**SOG**”, the “**Company**” or collectively with its subsidiaries, the “**Group**”) wishes to provide our responses to the following questions received from shareholders for the period from 9 to 20 April 2021 in relation to the Company’s upcoming Annual General Meeting on 23 April 2021:

Question 1

[Received from Shareholder: Mr. Chiang Kuo Chiang]

All the fifteen (15) clinics are branded with the "SOG" name except for "Joyce Lim Skin & Laser Clinic". Is there a reason for this exception? In particular, when I visited the clinic's website (<https://www.joycelim.com/>), there is no visual association with SOG at all. What is the rationale behind this inconsistent branding strategy?

Our Response

SOG acquired Dr. Joyce Lim’s (“**Dr. Lim**”) business and medical practices in 2015 (the “**Acquisition**”). The Acquisition provides the Group with in-roads into the practice of Dermatology which SOG was not formerly engaged in.

Dr. Lim comes with strong credentials and is a well-regarded skin specialist with more than two decades of experience. She also has a pool of regular customers that have stayed with her for many years. Joyce Lim Skin & Laser Clinic’s name and brand is well-recognised and established in the healthcare industry. As such, the Group has retained the name and brand for clear and easy identity for our patients and their families.

As part of the Group’s marketing effort, Dr. Lim and Joyce Lim Skin & Laser Clinic are included in all our marketing materials and content.

Question 2

[Received from Shareholder: Mr. Tan Kok Ching]

Can the management let shareholders understand how important is medical tourism to the company? Perhaps, management can reveal roughly how much, in percentage terms, medical tourists contribute to the company’s revenue before COVID-19? Is medical tourism in Singapore generally in decline trend due to stiff competition from other countries?

Our Response

The Group has four (4) business segments namely, Obstetrics & Gynaecology (“**O&G**”), Cancer-related, Dermatology and Paediatrics.

Due to the competition in neighbouring countries, Singapore's medical tourism is affected. While medical tourism is important to the Group, we are fortunate that our patients are mainly the locals and foreigners residing in Singapore. In general, we only have a small percentage of our patients who are medical tourists for our O&G and Paediatrics segment. We have approximately 30% of our patients who are medical tourists for our Cancer-related and Dermatology segments before COVID-19 situation.

Question 3

[Received from Shareholder: Mr. Tan Kok Ching]

The company seems to have lost its only breast cancer specialist, Dr. Lim Siew Kuan recently. Has the company thereby lost its breast cancer treatment capability? Is the company actively looking for a replacement?

Our Response

With the ageing population and cancer cases on the rise, we hope to continue strengthening our Cancer-related segment, deepening our specialist talent pool and expanding on our list of medical services being offered to our patients and their families.

In April 2021, we welcomed our new Colorectal Surgeon, Dr. Sim Hsien Lin ("**Dr. Sim**") on board. Dr. Sim was formerly a senior consultant with Khoo Teck Puat Hospital in the Department of General Surgery. Her expertise and key interests are colorectal surgery, proctology, minimally invasive surgery, and surgical management of inflammatory bowel diseases. Dr. Sim currently practises at SOG-HL Sim Colorectal, Endoscopy and General Surgery clinic, located at Mount Elizabeth Novena Specialist Centre #06-53.

As announced via SGXNet on 16 March 2021, we have renamed one of our direct wholly-owned subsidiary to SOG-CC Tan Breast, Thyroid & General Surgery Pte. Ltd. (the "**Arrangement**"). This Arrangement is for the recruitment of a new Breast & Thyroid Surgeon who will commence clinic operations in June 2021. The Company will share further information of our new Breast & Thyroid Surgeon on our website and social media platforms when he comes on board.

With the new Breast & Thyroid Surgeon on board, there will be three (3) specialist medical practitioners for Cancer-related segment.

Question 4

[Received from Shareholder: Mr. Tan Kok Ching]

The company has recently added to the list of cancer-related service by recruiting Dr. Sim, a Colorectal Surgeon. Is the company expanding its service beyond woman related cancer as well since colorectal cancer is not restricted to women?

Our Response

SOG's vision remains the same i.e. to be the premier specialist provider in holistic healthcare for women and children. We are committed to do our best for the care of our patients and their families. Apart from the O&G segment, our clinics in the other business segments (i.e. Cancer-related, Dermatology and Paediatrics) treat both male and female patients.

With the ageing population and cancer cases on the rise, we need to strengthen our Cancer-related segment and expand our list of medical services offering to our patients and their families. As colorectal cancer is one of the top diagnosed cancer for both men and women in

Singapore, the recruitment of our new Colorectal Surgeon, Dr. Sim, will help to take care of our patients and their families.

- END -

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Ms. Jennifer Tan, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.